Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

Journal of the National Cancer Institute

Volumn 96, Issue 11, 2004, Pages 879-882

  Saad, Fred ^a   Gleason, Donald M ^b   Murray, Robin ^c   Tchekmedyian, Simon ^d   Venner, Peter ^e   Lacombe, Louis ^f   Chin, Joseph L ^g   Vinholes, Jeferson J ^h   Goas, J Allen ⁱ   Zheng, Ming ⁱ  

^a NOTRE DAME HOSPITAL   (Canada)

^b Advanced Clinical Therapeutics   (United States)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d Pacific Shores Medical Group   (United States)

^e CROSS CANCER INSTITUTE   (Canada)

^f UNIVERSITÉ LAVAL   (Canada)

^g LONDON HEALTH SCIENCES CENTRE   (Canada)

^h Irmandade de Santa Casa Misericordia   (Brazil)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MITOXANTRONE; PLACEBO; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ARTICLE; BONE DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FATIGUE; FEVER; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; AGED; BONE TUMOR; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMIDAZOLES; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 2942518111     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh141     Document Type: Article

References (6)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(8 Suppl):1588-94.
2. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al.; Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
3. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982;10:1100-20.
4. Gleason D, Saad F, Goas A, Zheng M. Continuing benefit of zoledronic acid in preventing skeletal complications after the first occurrence in patients with prostate cancer and bone metastases [abstract 1522]. Proc ASCO 2003;22:379.
5. Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002;25(6 Suppl 1):S10-8.
6. Hillner BE, Ingle JN, Chelbowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042-57.